A new era of antithrombotic therapy in patients with atrial fibrillation

Harsh Golwala, Chadi Dib, Alfonso Tafur, Mazen S. Abu-Fadel

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Atrial fibrillation/flutter is the most common cardiac arrhythmia that can potentially result in stroke and death. For many years, aspirin and warfarin have been the cornerstone of stroke prevention among such patients. Although warfarin therapy has been advocated for patients with high likelihood of stroke, it requires close surveillance and monitoring, has a narrow therapeutic window and is quite often affected by medication interactions and diet. Thus, the need for a better and more consistent anticoagulant therapy was necessary and has been under development with various successes for many years. This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future.

Original languageEnglish (US)
Pages (from-to)128-135
Number of pages8
JournalAmerican Journal of the Medical Sciences
Volume344
Issue number2
DOIs
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Atrial Fibrillation
Stroke
Warfarin
Atrial Flutter
Therapeutics
Anticoagulants
Aspirin
Cardiac Arrhythmias
Diet

Keywords

  • Apixaban
  • Atrial fibrillation
  • Dabigatran
  • Newer anticoagulants
  • Rivaroxaban

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A new era of antithrombotic therapy in patients with atrial fibrillation. / Golwala, Harsh; Dib, Chadi; Tafur, Alfonso; Abu-Fadel, Mazen S.

In: American Journal of the Medical Sciences, Vol. 344, No. 2, 01.01.2012, p. 128-135.

Research output: Contribution to journalReview article

Golwala, Harsh ; Dib, Chadi ; Tafur, Alfonso ; Abu-Fadel, Mazen S. / A new era of antithrombotic therapy in patients with atrial fibrillation. In: American Journal of the Medical Sciences. 2012 ; Vol. 344, No. 2. pp. 128-135.
@article{3ef3270e46d840b5a480b80c56073f5d,
title = "A new era of antithrombotic therapy in patients with atrial fibrillation",
abstract = "Atrial fibrillation/flutter is the most common cardiac arrhythmia that can potentially result in stroke and death. For many years, aspirin and warfarin have been the cornerstone of stroke prevention among such patients. Although warfarin therapy has been advocated for patients with high likelihood of stroke, it requires close surveillance and monitoring, has a narrow therapeutic window and is quite often affected by medication interactions and diet. Thus, the need for a better and more consistent anticoagulant therapy was necessary and has been under development with various successes for many years. This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future.",
keywords = "Apixaban, Atrial fibrillation, Dabigatran, Newer anticoagulants, Rivaroxaban",
author = "Harsh Golwala and Chadi Dib and Alfonso Tafur and Abu-Fadel, {Mazen S.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1097/MAJ.0b013e3182429b1e",
language = "English (US)",
volume = "344",
pages = "128--135",
journal = "American Journal of the Medical Sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - A new era of antithrombotic therapy in patients with atrial fibrillation

AU - Golwala, Harsh

AU - Dib, Chadi

AU - Tafur, Alfonso

AU - Abu-Fadel, Mazen S.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Atrial fibrillation/flutter is the most common cardiac arrhythmia that can potentially result in stroke and death. For many years, aspirin and warfarin have been the cornerstone of stroke prevention among such patients. Although warfarin therapy has been advocated for patients with high likelihood of stroke, it requires close surveillance and monitoring, has a narrow therapeutic window and is quite often affected by medication interactions and diet. Thus, the need for a better and more consistent anticoagulant therapy was necessary and has been under development with various successes for many years. This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future.

AB - Atrial fibrillation/flutter is the most common cardiac arrhythmia that can potentially result in stroke and death. For many years, aspirin and warfarin have been the cornerstone of stroke prevention among such patients. Although warfarin therapy has been advocated for patients with high likelihood of stroke, it requires close surveillance and monitoring, has a narrow therapeutic window and is quite often affected by medication interactions and diet. Thus, the need for a better and more consistent anticoagulant therapy was necessary and has been under development with various successes for many years. This article will review 3 new antithrombotic medications that may potentially become the mainstay for treatment of patients with atrial fibrillation in the near future.

KW - Apixaban

KW - Atrial fibrillation

KW - Dabigatran

KW - Newer anticoagulants

KW - Rivaroxaban

UR - http://www.scopus.com/inward/record.url?scp=84864333850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864333850&partnerID=8YFLogxK

U2 - 10.1097/MAJ.0b013e3182429b1e

DO - 10.1097/MAJ.0b013e3182429b1e

M3 - Review article

C2 - 22245946

AN - SCOPUS:84864333850

VL - 344

SP - 128

EP - 135

JO - American Journal of the Medical Sciences

JF - American Journal of the Medical Sciences

SN - 0002-9629

IS - 2

ER -